drugset / Trial / NCT04537429
A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to investigate how the body absorbs, distributes, and get rid of eptinezumab when given directly into a vein.
Timeline
- Start
- 2020-08-04
- Primary completion
- 2022-10-20
- Completion
- 2023-08-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eptinezumab | Monoclonal antibody | 150 mg | Intravenous |
| Subject | Eptinezumab | Monoclonal antibody | 300 mg | Intravenous |